The Statistics and Data Center (SDC) of the Children's Oncology Group (COG) serve two important, distinct but related functions in COG. The first is to provide statistical sciences expertise in support of COG research through a staff of experienced Ph.D. level statisticians who are faculty members at major universities. These 'faculty' statisticians collaborate with COG investigators through their membership on COG study and scientific committees. They are assisted in this function by master-level statisticians and programmers who are also employed by the SDC. The second important function of the SDC is study and data operations - i.e., the coordination of COG research studies and the timely acquisition and storage of high quality data for COG studies, and interaction with COG institutions and study committees to ensure successful completion of COG studies. A staff of information technology professionals and research coordinators accomplish this SDC function. The COG SDC consist of two logically distinct departments or divisions: The first is the statistics department, which comprises the senior (Ph.D.) statisticians and assistant (M.S.) statisticians, plus some support staff. Although functioning as a united department, the members of this department are located at four main sites: The University of Southern California (USC)/Arcadia, the University of Nebraska/Omaha, the University of Florida/Gainesville and the University of Washington. The second division is data operations. This includes the Information Systems (IS) and computing staff which supports Remote Data Entry (RDE) and other necessary computing functions. All IS and computing staff will ultimately be located in Arcadia, although for the first two years of the grant period a small number will remain in Gainesville until the consolidation in Arcadia is complete. The division also includes a staff of research coordinators, who serve as the primary managers of studies and study data in the SDC, and who serve as the primary interface between the study committees, institutions, statisticians, the study development office and Group leadership, for all matters concerning data collection and related issues for ongoing COG studies. This staff is directed by a lead research coordinator who reports to the Group Statistician.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA098413-04
Application #
7013792
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
2003-06-20
Project End
2008-02-29
Budget Start
2006-06-29
Budget End
2007-02-28
Support Year
4
Fiscal Year
2006
Total Cost
$6,066,063
Indirect Cost
Name
National Childhood Cancer Foundation
Department
Type
DUNS #
624124301
City
Arcadia
State
CA
Country
United States
Zip Code
91006
Alexander, Thomas B; Gu, Zhaohui; Iacobucci, Ilaria et al. (2018) The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 562:373-379
Dix, David B; Seibel, Nita L; Chi, Yueh-Yun et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 36:1564-1570
Fernandez, Conrad V; Mullen, Elizabeth A; Chi, Yueh-Yun et al. (2018) Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol 36:254-261
Rau, Rachel E; Dreyer, ZoAnn; Choi, Mi Rim et al. (2018) Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer 65:
Burke, Michael J; Devidas, Meenakshi; Maloney, Kelly et al. (2018) Severe pegaspargase hypersensitivity reaction rates (grade ?3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leuk Lymphoma 59:1624-1633
Urtishak, Karen A; Wang, Li-San; Culjkovic-Kraljacic, Biljana et al. (2018) Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene :
Ariƫs, Ingrid M; Bodaar, Kimberly; Karim, Salmaan A et al. (2018) PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med 215:3094-3114
Gupta, Sumit; Devidas, Meenakshi; Loh, Mignon L et al. (2018) Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). Leukemia 32:1370-1379
Malempati, Suman; Weigel, Brenda J; Chi, Yueh-Yun et al. (2018) The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer :
Mansour, Marc R; He, Shuning; Li, Zhaodong et al. (2018) JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. J Exp Med 215:1929-1945

Showing the most recent 10 out of 473 publications